脑葡萄糖代谢是路易体病患者生存期的有价值的预测指标
研究纳入259例帕金森病、帕金森病痴呆或路易体痴呆患者,分析[18F]氟脱氧葡萄糖PET脑代谢对总生存期的预测价值。葡萄糖代谢是生存期的显著预测因子,视觉PET评分为严重、中度、轻度后皮质代谢减低者的中位生存期分别为4.8、6.8、12.9年,正常皮质代谢者未达中位生存期。
要点
- 葡萄糖代谢是路易体病患者生存期的显著预测因子(HR 1.4/ Z-score,HR 1.8/视觉PET评分)。
- 视觉PET评分为严重、中度、轻度后皮质代谢减低者中位生存期分别为4.8、6.8、12.9年。
- 基于预后指数的5组10年生存率分别为94.1%、78.3%、34.7%、0.0%、0.0%。
核心结论
- 区域脑葡萄糖代谢是路易体病生存期的显著预测因子,可能比临床里程碑「痴呆」更早预测生存期。
- [18F]氟脱氧葡萄糖PET可能改善治疗决策的基础,尤其是帕金森病的深部脑刺激等侵入性治疗。
研究设计与样本
- 纳入259例接受[18F]氟脱氧葡萄糖PET的帕金森病、帕金森病痴呆或路易体痴呆患者。
- 通过PD相关认知模式Z评分和视觉PET评级分析区域脑代谢,采用年龄和性别校正的Cox回归分析PET对总生存期的预测价值。
主要发现
- 葡萄糖代谢是259例患者生存期的显著预测因子(118例事件;Z评分每增加1分HR 1.4 [1.2-1.6];视觉PET评级评分每增加1分HR 1.8 [1.5-2.2];均p < 0.0001)。
- 视觉PET评级评分风险分层:严重、中度、轻度后皮质代谢减低患者的中位生存期分别为4.8、6.8、12.9年,正常皮质代谢者未达中位生存期。
- 基于预后指数分为5组,10年生存率分别为94.1%、78.3%、34.7%、0.0%、0.0%。
临床怎么用
- 区域脑葡萄糖代谢是路易体病生存期的显著预测因子,可能允许比临床里程碑「痴呆」更早预测生存期。
- [18F]氟脱氧葡萄糖PET可能改善治疗决策的基础,尤其是帕金森病的深部脑刺激等侵入性治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with Lewy body diseases have an increased risk of dementia, which is a significant predictor for survival. Posterior cortical hypometabolism on [18F]fluorodeoxyglucose positron emission tomography (PET) precedes the development of dementia by years. We therefore examined the prognostic value of cerebral glucose metabolism for survival. METHODS: We enrolled patients diagnosed with Parkinson's disease (PD), Parkinson's disease with dementia, or dementia with Lewy bodies who underwent [18F]fluorodeoxyglucose PET. Regional cerebral metabolism of each patient was analyzed by determining the expression of the PD-related cognitive pattern (Z-score) and by visual PET rating. We analyzed the predictive value of PET for overall survival using Cox regression analyses (age- and sex-corrected) and calculated prognostic indices for the best model. RESULTS: Glucose metabolism was a significant predictor of survival in 259 included patients (n = 118 events; hazard ratio: 1.4 [1.2-1.6] per Z-score; hazard ratio: 1.8 [1.5-2.2] per visual PET rating score; both p < 0.0001). Risk stratification with visual PET rating scores yielded a median survival of 4.8, 6.8, and 12.9 years for patients with severe, moderate, and mild posterior cortical hypometabolism (median survival not reached for normal cortical metabolism). Stratification into 5 groups based on the prognostic index revealed 10-year survival rates of 94.1%, 78.3%, 34.7%, 0.0%, and 0.0%. INTERPRETATION: Regional cerebral glucose metabolism is a significant predictor of survival in Lewy body diseases and may allow an earlier survival prediction than the clinical milestone "dementia." Thus, [18F]fluorodeoxyglucose PET may improve the basis for therapy decisions, especially for invasive therapeutic procedures like deep brain stimulation in Parkinson's disease. ANN NEUROL 2024;96:539-550.
引用
- Brumberg J, Blazhenets G, Bühler S, et al. Cerebral Glucose Metabolism Is a Valuable Predictor of Survival in Patients with Lewy Body Diseases. Ann Neurol. 2024. PMID: 38888141. doi:10.1002/ana.27005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。